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ABSTRACT 
AMINOGLYCOSIDE-ASSOCIATED DIZZINESS IN GERIATRIC 
PATIENTS: A PROSPECTIVE OBSERVATIONAL COHORT STUDY. 
Richard G. Ihnat and Mary E. Tinetti. Department of Internal Medicine, 
Yale University, School of Medicine, New Haven, CT. 
To determine if the elderly have an increased risk of aminoglycoside- 
induced vestibular damage, 42 subjects over the age of 65 who had received at 
least five consecutive days of either an aminoglycoside (exposed subjects) or 
one of a list of control antibiotics (unexposed subjects) were questioned as to 
the presence of dizziness symptoms after their discharge from the hospital. 
Laboratory and diagnostic data were also abstracted from their medical 
records. 
Two exposed subjects (13%) and 2 unexposed subjects (8%) reported a 
new-onset of dizziness since their hospitalization (p=0.63). Dizziness increased 
in severity for 3 (19%) exposed and 2 (8%) unexposed subjects (p=0.36). An 
overall worsening of dizziness was noted in 3 (19%) exposed and 3 (12%) 
unexposed subjects (p=0.66). Although these differences were not statistically 
significant due to the low power of the study, they indicate a trend may be 
present. We conclude that an increased risk of dizziness symptoms secondary 
to aminoglycoside administration has not been proven but may be present and 
warrants continuation of this study. 
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INTRODUCTION 
The aminoglycoside antibiotics have long been known to have significant 
side-effects which include nephrotoxicity and vestibular and auditory toxicity. 
Despite their long tenure in our clinical armamentarium, the exact mechanism 
of their bactericidal and toxic side-effects remains elusive. The elderly are a 
unique population which may have an increased susceptibility to the toxic side- 
effects. This pilot study will specifically address the latter issue. 
An understanding of the vestibular system is crucial to understanding 
aminoglycoside toxicity. A review of this system will be followed by 
discussions of aminoglycoside usage, bacterial toxicity, human toxicities, and 
how they relate to the elderly. 
THE VESTIBULAR SYSTEM 
In humans, the vestibular system is responsible for maintaining balance, 
coordinating eye, head, and body movements, and enabling the eye to fixate 
on a point while the head is moving. The membranous labyrinth of the middle 
ear’s vestibular apparatus is composed of three semicircular canals, which are 
oriented in planes 90 degrees apart, and the saccule and the utricle. These 
structures are housed in the bony labyrinth of the petrous bone and are 
separated from it by a fluid called perilymph. The semicircular canals supply 
information about angular acceleration of the head while the utricle provides 
information about linear acceleration and head position with respect to gravity. 
The function of the saccule is unknown but is felt to be similar to that of the 
utricle. The lumens of these structures are connected with each other as well 
as with the cochlea, and they are filled with a common pool of fluid called 
endolymph (Kandel & Schwartz, 1985). 
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The vestibular hair cells are the key sensory cells, and they are located 
in the ampullae of the semicircular canals and the macula of the utricle. On 
its luminal membrane, each hair cell has one kinocilium and several stereocilia 
which project into the endolymph. These projections are oriented along the 
cell membrane so that the kinocilium is lateral to the stereocilia. When the 
head accelerates, the viscous endolymph lags behind which causes it to move 
relative to the hair cells of the semicircular canals. When the force of the fluid 
bends the stereocilia towards the kinocilium, the cell depolarizes. When they 
bend away from the kinocilium, the hair cell hyperpolarizes. In this manner, 
variations from the hair cell’s baseline rate of 15 impulses per second code for 
the direction of the movement. The number of cells recruited delineates the 
magnitude of the acceleration (Kandel & Schwartz, 1985). 
The utricle works in a manner analogous to the semicircular canals, but 
motion of tiny crystals called otolith, which are embedded in a gelatinous 
matrix, is substituted for the motion of the endolymph. The otolith are 
composed of calcium carbonate and rest on the hair cell cilia. With the head 
in anatomical position, the macula of the utricle is in the horizontal plane. As 
the force of gravity acts on the otolith which rest on the stereocilia, the cilia 
are bent causing them to either hyperpolarize or depolarize depending on the 
head’s orientation to gravity (Kandel & Schwartz, 1985). 
Impulses from the hair cells of the canals and utricle are transmitted to 
bipolar cells in the vestibular ganglia of the eighth nerve where the data is 
integrated to provide information about the position and motion of the head. 
Much of this data is transmitted into the cerebellum, median longitudinal 
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fasciculus, reticular formation, and spinal cord and thus remains 
predominantly in the unconscious realm. In concert with information provided 
by the other senses, vestibular input is crucial for movement and balance. 
When any part of the vestibular system breaks down, dizziness, nausea, 
and ataxia result. The hair cells, which are one of the key components, are 
vulnerable to a wide variety of insults, among which are the toxic effects of 
drugs. This study investigated the effects of the aminoglycoside antibiotics on 
the vestibular system in elderly patients. 
Of the several tests used to determine if the vestibular system is intact, 
the thermal test and the Romberg test are the most common. In the thermal 
test, either warm or cold water is dropped into the external acoustic meatus to 
simulate acceleration. This local change in temperature sets up convection 
currents in the endolymph which causes the fluid to move and influence the 
hair cells. In the normal individual, this results in nystagmus. If nystagmus 
is depressed or eliminated, it indicates the presence of vestibular dysfunction. 
The Romberg test evaluates the utricle testing the subjects ability to maintain 
balance when deprived of visual cues. 
These tests, however, are somewhat insensitive, and it is difficult to 
quantitate the degree of vestibular dysfunction. Dizziness, being the clinical 
manifestation of vestibular dysfunction, is likewise difficult to assess or 
quantitate. Thus, dizziness is largely a subjective experience which can be 
reported but not satisfactorily tested. Consequently, this study focused on 




Aminoglycoside antibiotics are derived from the soil actinomycetes 
Streptomyces and Micromonospora, and they were first discovered by Selman 
Waksman’s group at Rutgers University in 1944 (Schatz et al., 1944). The 
aminoglycosides are stable, hydrophilic, polycationic amino sugars bound in 
a glycosidic linkage to a central hexose sugar. For systemic administration, 
they must be administered parenterally secondary to poor oral absorption, and 
their polycationic structure is the basis for their poor central nervous system 
penetration. They are distributed predominantly in the extracellular space 
compartment, and they are excreted unmetabolized by the kidney with a half- 
life of about two hours. The antimicrobial effects of gentamicin, tobramycin, 
and netilmicin are usually achieved at peak serum concentrations of 4-8 
mcgs/ml, and kanamycin is effective at 15-40 mcgs/ml. Streptomycin and 
amikacin are efficacious at 20-30 mcgs/ml. Aminoglycosides kill in a 
concentration-dependent manner. The higher the concentration, the faster the 
bacteria are killed (Lampe, 1986; Gilman, 1985). 
Clinically, the most commonly used aminoglycosides are streptomycin, 
kanamycin (Kantrex, Kebcil), neomycin (Mycifradin, Neobotic), gentamicin 
(Garamycin), tobramycin (Nebcin), amikacin (Amikin), netilmicin 
(Netromycin), paromycin (Humatin), dibekacin, and sisomicin (Siseptin). As 
a class, single-agent aminoglycoside therapy is primarily used against aerobic 
gram-negative bacilli (Lampe, 1986; Gilman et al., 1985). The aminoglycosides 
are also commonly used in combination with other antibiotics with which they 
act synergistically. Such combinations typically include cell wall inhibitors. 
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such as beta-lactams or vancomycin, which are believed to damage the 
peptidoglycan cell wall and allow the aminoglycosides easier access to the 
bacterial cytoplasm (Plotz & Davis, 1962). This is done in serious infections 
such as bacteremia, peritonitis, nosocomial pneumonia, osteomyelitis, septic 
arthritis, burns, pyelonephritis, and meningitis where gram-negative bacilli are 
either proven or suspected (John, 1988; Lampe, 1986 & Gilman et al., 1985). 
Of particular concern is Pseudomonas aeruginosa coverage. Gentamicin, 
tobramycin, and amikacin are particularly effective in this regard. 
MECHANISM IN BACTERIA 
There are significant pharmacokinetic differences among the 
aminoglycosides, and they may therefore have different methods of transport 
and action (Taber et al., 1987; Arrow & Taber, 1986). As a class, unlike the 
penicillin and cephalosporins, they must enter the bacteria in order to be 
bactericidal. The bacterial capsule (when present), outer membrane, and cell 
wall do not seem to be a significant impediment to penetration (Taber et al., 
1987; Miller et al., 1986; Peterson et al., 1985; Nichols & Slack; Nakae & 
Nakae, 1982). It is interesting to note, however, that the proposed mechanism 
for the synergy between beta-lactams and aminoglycosides is that the beta- 
lactam damages this wall and allows the aminoglycosides easier access to the 
cytoplasm (Miller et al., 1986; Plotz & Davis, 1962). Therefore, if the cell wall 
is not a significant barrier, a new explanation for this synergy must be sought. 
The process by which aminoglycosides cross the inner membrane has 
engendered the greatest controversy. Bryan & Van Den Elzen (1976) proposed 
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an overview of the process in which aminoglycoside uptake is divided into 
three phases. The first phase involves ionic binding to the inner membrane in 
an energy-independent manner. In gram-negative bacteria, they would bind 
to lipopolysaccharides, phospholipids, and outer membrane proteins while in 
gram-positive bacteria, they would bind to phospholipids and teichoic acids 
(Taber et al., 1987). In energy-dependent phase I (EDPI) the positively 
charged aminoglycosides associate with membrane "transporters” and small 
amounts are shuttled across the membrane traveling down the electrical 
potential energy gradient to the relatively negatively charged interior of the 
cell. The slow leak of aminoglycoside into the cell during EDPI may occur at 
zones of growth or through faulty protein channels which may normally exist 
in nature (Davis et al., 1986). 
After small quantities of drug have entered the cell during EDPI and 
have bound to ribosomes, energy-dependent phase II (EDPII) begins and 
allows more rapid entry of large amounts of antibiotics into the cells (Bryan 
& Van Den Elzen, 1976). Once inside the cell, the aminoglycosides bind 
almost irreversibly to the 30S ribosomal subunit to create a nonfunctional 
complex which blocks initiation of runoff (free) ribosomes and causes 
misreading of the genetic code in polysomes. Irreversible binding to ribosomes 
and subsequent loss of protein synthesis is probably at least part of the 
mechanism for bacterial cell death (Taber et al., 1987). 
Membrane potential (Mates et al., 1983; Miller et al., 1980), active 
electron transport (Arrow & Taber, 1986; Campbell et al., 1980), and 
functioning ribosomes (Taber et al., 1987; Muir et al., 1984; Davis, 1982) are 
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necessary for the rapid uptake of aminoglycosides during EDPII. These 
factors may be related through the functioning of the ATP synthase molecule. 
Normally, this enzyme produces ATP when the proton motive force overcomes 
a threshold value. Alternatively, the enzyme can consume ATP to create a 
proton motive force. After working with E. coli mutants possessing various 
combinations of functional and non-functional components of the enzyme, 
Humbert and Altendorf (1989) proposed that inactive enzymes would allow 
proton motive force, and therefore membrane potential, to rise and reach a 
threshold level required for aminoglycoside uptake without converting the 
proton motive force into ATP. On the other hand, dysfunctional enzymes 
which act as proton pores lower the proton motive force, and hence the 
membrane potential, below the threshold limit for aminoglycoside uptake. 
This understanding can be used to construct a model of aminoglycoside 
entry. After small quantities of aminoglycoside have entered the cell during 
EDPI and altered protein synthesis (Davis et ah, 1986), inactive ATP synthase 
would be produced. Under conditions of active electron transport, the 
membrane potential would rise. Since the inactive ATP synthase could not 
convert the membrane potential to ATP, it would rise uncontrollably. The 
elevated membrane potential would then drive aminoglycoside molecules 
through other pores created by faulty RNA translation. 
The human mitochondria shares some similarities with bacterial cells in 
that it has an electron transport chain and bacteria-like ribosomes. 
Nevertheless, it is unclear which, if any, of the steps in bacterial cell death are 




The side effects of the aminoglycosides, which have a low 
therapeutic/toxic ratio compared to other antibiotics, are well-known. 
Ototoxicity, nephrotoxicity, neuromuscular blockade, skin rash, drug fever, 
gastrointestinal upset, malabsorption, blood dyscrasias, transaminitis, retinal 
damage, and peripheral neuropathies have all been described (Judson, 1989; 
Edson & Terrell, 1987; Lampe, 1986 & Gilman, et ah, 1985). The clinical 
practice of measuring serum peak and trough levels of the aminoglycosides is 
an attempt to avoid subjecting patients to unnecessarily high doses of these 
drugs in the hope of minimizing the side effects. There are also several 
significant drug interactions which must be considered. Nephrotoxicity can be 
produced by concurrent administration of methoxyflurane (Penthrane), 
amphotericin B (Fungizone), vancomycin, cisplatin (Platinol), cyclosporine 
(Sandimmune), indomethacin(IndocinIV),cephalothin(Keflin),cephaloridine, 
and loop diuretics such as furosemide (Lasix), bumetanide (Bumex), and 
ethacrynic acid. Additionally, neuromuscular blockade has been reported 
when succinylcholine (Anectine, Quelicin, Sucostrin) or tubocurarine were used 
concomitantly with aminoglycosides (Lampe, 1986). Furthermore, in the 
guinea pig, Brummett (1981) demonstrated that concurrent use of loop 
diuretics and aminoglycosides results in significantly enhanced ototoxicity. 
Of the aminoglycoside side-effects nephrotoxicity and ototoxicity are the 
most common. The term ototoxicity encompasses both auditory and vestibular 
toxicity. Of these three side-effects, vestibular damage is the most difficult to 
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measure and quantitate. Perhaps for this reason, most of the work in the 
scientific literature has focused on renal and auditory toxicity. 
NEPHROTOXICITY 
The effect of aminoglycosides on the kidney has been extensively 
studied, and the incidence of nephrotoxicity is estimated to be 3-26% of all 
patients (Smith et al., 1980; Appel & Neu, 1977). Risk factors include 
hypotension, hypovolemia, advanced age, obesity, recent prior aminoglycoside 
therapy, duration of treatment, preexisting renal insufficiency, and elevated 
serum drug levels (Appel, 1990; Corcovan et al., 1989; Edson & Terrell, 1987; 
Lampe, 1986; Cabrera et al., 1982). 
Aminoglycoside nephrotoxicity begins with proteinuria, enzymuria and 
cylinduria. There is a decrease in GFR which leads to elevated BUN and 
serum creatinine levels and the onset of usually nonoliguric failure seven to ten 
days into therapy (Appel, 1990). These effects are reversible and cumulative 
(Edson & Terrell, 1987). 
Houghton’s group (1988) administered subtherapeutic doses of 
gentamicin to rats so that the serum levels were either low or unmeasurable for 
a period of six months and found that their kidneys progressed from mild 
chronic tubulointerstitial nephritis to progressive renal failure. Although 
aminoglycosides would never be given in this fashion, it suggests that even 




The rat is an excellent model of nephrotoxicity, and Silverblatt (1982) 
and Appel (1990) summarized this work. After binding to phospholipid 
receptors on the brush border of the tubular cells, gentamicin is reabsorbed 
from the glomerular filtrate mainly in the proximal tubule by pinocytosis and 
stored in lysosomes. Some also remains in the cytoplasm (Wedeen et al., 
1983). Lysosomal storage accounts for the relatively high concentration found 
in renal cortex and may involve irreversible binding to various cellular 
constituents (Oshima et al., 1989). Gentamicin is then excreted into the urine 
by reverse endocytosis and enjoys a half-life of seven days. While in the 
lysosome, high concentrations of gentamicin cause the membrane to become 
leaky and inhibit the degradation of complex lipids. As these lipids build up, 
they form the myeloid bodies which are seen with electron microscopy. 
Gentamicin also damages the mitochondria which in turn leads to a depletion 
of ATP (Simmons et al., 1980) and changes in subcellular calcium 
compartmentalization. Other cellular changes include an inhibition of the 
Na/K ATPase (Lipsky & Lietman, 1980) and a decrease in apical membrane 
marker enzymes levels (Inui et al., 1988). Once proximal tubule cell damage 
occurs, it is "translated" into a declining GFR possibly through 
vasoconstrictive hormones or backleak of waste across the damaged 
epithelium. It is difficult to discern which changes are significant and which 
are merely epiphenomena. It is also difficult to determine which effects are 
common to the mechanism of hair cell death seen in ototoxicity since the 




Aminoglycoside ototoxicity involves irreversible, dose-related damage to 
the hair cells of the cochlea and vestibular apparatuses of the inner ear. 
Auditory toxicity is conventionally taken to mean at least a 15dB decrease in 
hearing acuity in the range from 250-8,000 Hz, and vestibular toxicity is a loss 
of nystagmus in the thermal test. The human attack rate for auditory toxicity, 
with gentamicin and tobramycin, is 10-11% (Smith et al., 1980). Brummett & 
Morrison (1990), however, used the same criteria on a group of healthy 
volunteers who were not receiving any medications and found that 20-33% of 
the subjects met the criteria for new-onset auditory toxicity during the course 
of study. They concluded that the incidence of this complication was probably 
overrated. 
Since most large studies have focused on auditory damage as a measure 
of aminoglycoside ototoxicity, it is difficult to obtain reliable estimates for 
vestibular toxicity. Estimates from some of the larger studies of the rate in the 
general population range from 0.4% - 2.5% for most of the aminoglycosides 
(Arcieri et al. 1970; Neu & Bendush, 1976), but with streptomycin, the estimate 
is close to 20% (Wilson et al., 1984)[Table 1]. Of the aminoglycosides, 
kanamycin, neomycin, and amikacin primarily affect hearing while gentamicin 
and streptomycin seem to chiefly affect the vestibular system. Tobramycin 
seems to cause both types of ototoxicity equally (Edson & Terrell, 1987; 
Lampe, 1986; Gilman et al., 1985). 
Clinically, patients with auditory toxicity often complain of tinnitus or 




AMINOGLYCOSIDE TOXICITY RATES 
AGENT N AUDITORY VESTIBULAR CITATION 
gentamicin 34 N/E 10.0% Nordstrom etal., 1973 
1484 2.3% 2.5% Jackson & Arcieri, 1971 
1327 1.3% 2.0% Arcieri et al., 1970 
26 3.8% 3.8% Lerner et al., 1977 
45 0.0% 16.0% Tjernstrom et al., 1973 
40 7.5% 23.0% Meyers, 1970 * 
181 N/E 2.2% Waisbren, 1969 
138 16.0% 15.0% Fee, 1980 
streptomycin 36 N/E 19.0% Wilson et al., 1984. 
tobramycin 138 15.0% 4.6% Fee, 1980 
3506 0.3% 0.4% Neu & Bendush, 1976 
amikacin 1548 4.6% 0.7% Lane et al., 1977 
27 7.4% 0.0% Lerner et al., 1977 
55 24.0% 0.0% Black et al., 1976 
kanamycin 81 24.0% 9.9% Finegold et al., 1958 
N/E = Not Evaluated 
* = dosage not adjusted for renal insufficiency 
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permanent high frequency hearing loss (Lampe, 1986). Vestibular damage is 
often manifest by a moderate head ache in the early stage lasting 1-2 days. 
This is followed by 1-2 weeks of nausea, vomiting, vertigo, dizziness, an 
inability to perceive termination of movement ("mental past pointing"), 
difficulty focusing and reading, a positive Romberg test, and nystagmus. The 
chronic phase begins suddenly and is heralded by ataxia and lasts for two 
months. The compensatory stage in which the patient learns to adapt using 
visual cues follows gradually until the symptoms only become apparent when 
the eyes are closed. In cases where the damage is not permanent, this 
recuperation may take more than a year, and recovery is less satisfactory in 
older patients (Gilman et al., 1985; Neu & Bendush, 1976). Moreover, the 
onset is variable and can be quite rapid. Miyoshi(1988) examined patients with 
tuberculosis or urological infections and found that some had their first 
symptoms after less than five days of treatment. Others have reported a 
delayed response in which the symptoms don’t appear until several weeks after 
the drugs are discontinued (Neu & Bendush, 1976). 
MECHANISM IN HUMANS 
The exact mechanism of vestibular hair cell injury and how it relates to 
the nephrotoxic or bactericidal mechanisms discussed previously is still not 
clear. Much of the work has been done on the hair cells of the organ of Corti, 
but since aminoglycosides seem to damage both vestibular and auditory hair 
cells, the results are probably applicable to both. Some of the renal data may 
also be applicable. 
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That the aminoglycosides damage hair cells is clear. Animal studies 
have demonstrated that lesions occur at both the inner hair cells of the organ 
of Corti and the vestibular hair cells (Theopold, 1977; Wersall et ah, 1973; 
McGee et ah, 1969; Koide et ah, 1966; Duvall & Wersall 1964). The results 
of these studies also show the eighth nerve to be spared. Huizing & de Groot 
(1987) reviewed the human data and determined that in the cochlea, outer hair 
cells are affected first before the inner hair cells. The stria vascularis is also 
injured. Finally, the supporting structures and nerves rapidly degenerate 
secondary to hair cell loss and not due to direct drug toxicity. They did not 
look at the vestibular hair cells. 
The highest concentrations of aminoglycosides in the body occur in the 
endolymph, perilymph, and kidney - the areas where toxicity is the greatest. 
Federspil, et al. (1976) examined the perilymph of guinea pigs after a 
subcutaneous bolus injection of aminoglycoside and found that the drug 
concentration in the perilymph rose gradually bilaterally until it was equal to 
that of the serum. Beyond that point, the serum concentration began to drop 
quite precipitously, but levels in the perilymph decreased very slowly. Indeed, 
after 5 hours the aminoglycoside concentration in the middle ear was much 
higher than in brain, heart, and liver. From their data, they were able to 
calculate the perilymph half-lives for gentamicin (12 hours), tobramycin (11 
hours), and amikacin (10 hours). 
This accumulation is also seen in rats, where Huy et al. (1983) detected 
gentamicin in the endolymph up to 15 days after administration of the drug 
was discontinued. Whereas the serum half-life of gentamicin in the rat is only 
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40 minutes, they were unable to even calculate the half-life in the endolymph. 
In humans, the half-lives of the aminoglycosides in the endolymph are up to 
four times greater than the serum half-lives (Neu & Bendush 1976). The exact 
clinical significance of this is unclear, but this prolonged exposure may impair 
the ability of the cells to maintain the proper cation concentrations in the 
endolymph and thus may lead to reversible ototoxicity (Neu & Bendush 1976). 
This effect can be quite rapid. Direct injection of aminoglycoside into guinea 
pig endolymph produces an immediate suppression of cochlear function 
(Konishi, 1979). Wilson & Ramsden (1977) obtained similar results in humans 
with systemic bolus administration, and they noted the effects to be rapid and 
reversible. They suspected this rapidity ruled out interruption of protein 
synthesis as a possible mechanism. Rather, they speculated that toxicity was 
due to interference with energy metabolism or cation transport. Permanent 
ototoxicity due to cell death would then result from either the long-term loss 
of these gradients or to direct toxic effects on hair cells by the aminoglycosides. 
Early theories as to the mechanism of the toxic side-effects implicated 
the ribosomes (Spoendlin, 1966) or the cell membrane (Wersall & Flock, 1964). 
Many of the current theories have focused on phospatidyl inositol (PI) 
metabolism. The PI cycle is an important second messenger system which is 
known to be activated by gonadotropin releasing hormone and vasopressin and 
is part of the alpha-one adrenergic receptor in liver tissue (Patton et al., 1989; 
Zubay, 1983). Moreover, it is activated in platelet by thrombin and collagen 
to promote platelet aggregation (Polascik, 1987). When these cell membrane 
receptors are occupied, phospholipase C (PLC) cleaves PI into diacylglycerol 
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(DG) and inositol 1,4,5 triphosphate (IP?). 1P^ liberates calcium from the 
endoplasmic reticulum until it is degraded to inositol. DG, in the presence of 
the calcium liberated by IP3, activates membrane-bound kinase C. Kinase C 
phosphorylates various cellular proteins and thus may control cellular division. 
DG is then phosphorylated to become phosphatidic acid (PA). After PA 
combines with cytosine triphosphate and inositol, IP3 is regenerated and the 
cycle may begin again (Patton, 1989). An alternative pathway involves the 
action of diacylglycerol lipase upon PA to form arachidonic acid, the precursor 
to prostaglandin synthesis (Zubay, 1983). 
Interest in PI metabolism as the molecular site of injury in 
aminoglycoside toxicity began when Schacht (1976) took subcellular fragments 
of guinea pig cerebral cortex and found that neomycin bound to the 
polyphosphoinositide component. Polyphosphoinositides are found in the 
highest concentrations in neural tissue (Hauser & Eichberg, 1973). Schacht 
speculated that by binding to it, neomycin may block polyphosphoinositide 
from acting as a substrate for phosphorylation and thus interfere with 
membrane function. Lodhi and associates (1979) duplicated this work by 
demonstrating that neomycin binds to an artificial monomolecular membrane 
of polyphosphoinositide. In addition, they found that it displaced calcium 
from the membrane. From this observation, they postulated that neomycin 
may act by blocking calcium that is necessary for membrane function. 
Furthermore, it is known that aminoglycosides competitively inhibit 
renal cytoplasmic PLC, possibly due to their structural similarity to PI (Lipsky 
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& Lietman, 1982). Not only would this alter the response of the second 
messenger system, but also it would increase the concentration of PI. 
Renal phospholipase A (PLA), which degrades neutral lipids, is 
synergistically inhibited by aminoglycosides and PI (Hostetler & Jellison, 1990). 
Hostetler & Jellison (1990) proposed that the aminoglycosides bind to PI, 
which is not normally a substrate of PLA, to create a new conformation which 
prevents PLA from interacting with its usual substrate. Clearly, 
aminoglycoside inhibition of PLC would lead to an accumulation of PI and 
subsequently inhibition of PLA. This chain reaction might then cause a build¬ 
up of neutral phospholipids and myeloid body formation. 
Support for this hypothesis comes from lipid analysis of membranes in 
renal cells treated with aminoglycosides. Feldman and coworkers (1982) found 
that the increase in PI concentration was an early effect and hence may be part 
of the pathogenesis. Since aminoglycosides are known to bind with PI at the 
apical membrane, they postulated that it might also be related to uptake. PI, 
though, is not one of the predominant lipids in myeloid body formation in 
fibroblasts (Oshima et al., 1989). Rather, phosphatidyl choline, bis- 
(monoacylglycerol) phosphate, and phosphatidylserine show the greatest 
increase. Oshima’s group (1989) further suggested that actual myeloid body 
formation may not be the cytotoxic mechanism, but rather, cytotoxicity may 
result from aminoglycoside binding to organelles other than lysosomes. 
PI is located on the inner leaflet of the cell membrane, so clearly, to 
affect these molecules, aminoglycosides must somehow enter the cytoplasm of 
the hair cells. There is evidence that this occurs early during exposure to 
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aminoglycosides (Wedeen et al., 1983). In fact, aminoglycoside sequestration 
in the lysosome may even be an adaptive response to protect the cell from 
damage (Williams et al., 1984; Wedeen et al, 1983). 
Simmons and associates (1980) found that mitochondria of rat kidneys 
treated with gentamicin had decreased cellular respiration, and the cells had 
less ATP than controls. The parallel with bacterial cytochrome systems is 
inescapable. It would be reasonable to presume that the inhibition of Na/K 
ATPase seen in renal cells might also apply to hair cells. For a hair cell which 
depends on membrane potential for its function, this inhibition might also 
affect cell viability. Other intracellular aminoglycoside effects would include 
inhibition of protein kinase C (Hagiwara et al., 1988) and stimulation of 
messenger-independent protein kinases (Ahmed et al., 1988). 
It is unclear which of these observations are related to the actual 
mechanism of cytotoxicity and which are epiphenomena. It does seem, 
however, that PI metabolism is a crucial factor. Further research needs to be 
done to discover exactly how these compounds affect bacteria and how it 
relates to hair cell death and other side-effects. 
RISK FACTORS 
In the various studies of the ototoxic effects of the aminoglycoside 
antibiotics, several factors have been identified which seem to be correlated 
with increased risk of vestibular damage [Table 2]. Renal insufficiency 
(especially when aminoglycoside dosage is not adjusted accordingly), high 
serum concentrations of the drug, duration of therapy, and previous treatment 
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with aminoglycosides have been noted as factors by multiple authors (Edson 
& Terrell, 1987; Arcieri et al., 1970; Jackson & Arcieri, 1971; and Wilson et al., 
1984; Nordstrom et al., 1973). Obesity, preexisting auditory impairment, 
bacteremia, dehydration, and poor liver function have also been implicated 
(Gilman et al., 1985). 
In their work on aminoglycoside side-effects, Moore and associates 
(1984) surveyed 135 patients who had received at least 9 doses of 
aminoglycoside antibiotics. They found total dose, duration of therapy, peak 
temperature, bacteremia, liver dysfunction, and dehydration to be risk factors 
for hearing loss. To explain some of these results, they speculated that if 
prostaglandin E is cytoprotective against the effects of bacterial endotoxins or 
leukocyte pyrogen on the hair cells, then aminoglycosides might be indirectly 
responsible by blocking PLC (Lipsky & Lietman, 1982). PLC cleaves DG 
from PI which can serve as a precursor of arachidonic acid and eventually 
prostaglandin E (Zubay, 1983). Furthermore, they postulated that the 
increased risk in those with liver dysfunction might somehow be related to 
CNS depression seen in liver failure. They were unable to correlate hearing 
loss with hematocrit, age, bicarbonate concentration, sex, presence of urinary 
tract infection or pneumonia, prognosis, or use of clindamycin, cephalothin, 
or furosemide. They did not examine vestibular toxicity. 
Another potential risk factor is poor nutrition. In guinea pigs that were 
food-restricted (but received water ad lib), Prazma and coworkers (1983) noted 
enhanced hair cell death in those subjects that received tobramycin or 




AMINOGLYCOSIDE OTOTOXICITY RISK FACTORS 
RISK FACTOR TOXICITY* MODEL** CITATION 
renal insufficiency V H Nordstrom et ah, 1973 
V,A H Finegold et al., 1958 
V H Tjernstrom et al., 1973 
A H Fee, 1980 
V,A H Neu & Bendush, 1976 
prior treatment V,A H Edson & Terrell, 1987 
V H Wilson et al., 1984 
V H Tjernstrom et al., 1973 
high serum concen. V,A H Edson & Terrell, 1987 
V H Wilson et al., 1984 
V H Nordstrom et al., 1973 
V,A H Finegold et al., 1958 
treatment duration V H Nordstrom et al, 1973 
A H Moore et al., 1984 
high temperature A H Fee, 1980 
A H Moore et al., 1984 
A A Flenry et al., 1983 
semistarvation A A Prazma et al., 1983 
noise A A Brown et al., 1980 
A A Jauhiainen et al., 1978 
liver dysfunction A H Moore et al., 1984 
bacteremia A H Moore et al., 1984 
dehydration A H Moore et al., 1984 
total dose A H Moore et al., 1984 
auditory dysfunct V H Tjernstrom et al., 1973 
hematocrit V H Fee, 1980 
other drugs V,A H Neu & Bendush, 1976 
* vestibular toxicity = V, auditory toxicity = A 
** human data = H, animal data = A 
auditory dysfunct = a history of preexisting auditory dysfunction, 




that the decreased glomerular filtration rate seen with semistarvation may 
increase serum levels of the drug and thereby lead to ototoxicity. 
Noise has been shown to potentiate the auditory toxicity of the 
aminoglycosides. In the cochlea. Brown and associates (1980) using kanamycin 
and Jauhiainen and colleagues (1972) using neomycin found the number of 
hair cells lost by subjecting guinea pigs simultaneously to both noise and 
kanamycin far outstripped the sum of the two agents when used alone. Since 
Hawkins (1971) has shown that noise causes vascular changes which induce 
hair cell ischemia. Brown and coworkers (1980) suggested that noise renders 
the cells more vulnerable to the effects of aminoglycosides. Noise, however, 
had no effect on the pharmacokinetics of kanamycin, and it has never been 
shown to be a factor in vestibular toxicity. 
Finally, observing that preweanling mice exposed to elevated 
temperatures suffered from increased aminoglycoside ototoxicity as measured 
by electrocochleography, Henry and associates (1983) speculated that fever 
might also be a risk factor in humans. They postulated that increased 
metabolic demands from hyperthermia could leave the hair cells more 
vulnerable, and they suggested that noise and even hyperthyroidism might 
work in the same fashion. They attempted to control for dehydration with 
daily weighings and injections of dilute solutions of aminoglycosides. 
Nevertheless, dehydration may also have played a role. They did not examine 




The elderly are a unique population when it comes to pharmaco- 
therapeutics, and many authors have speculated that they might have an 
increased risk of vestibular damage (Edson & Terrell, 1987; Lampe, 1986; 
Appel & Neu, 1978; Nordstrom et ah, 1973; and Tjernstrom et al, 1973). 
Studies on vestibular toxicity among elderly patients, however, have not 
confirmed this speculation (Fee, 1980; Lane et ah, 1977; Lerner et ah, 1977; 
Neu & Bendush, 1976; Nordstrom et ah, 1973; and Finegold et ah, 1958). One 
reason for the negative research findings is the low incidence rate and low 
power of some of the studies. Jackson & Arcieri (1971) reviewed 70 of the 72 
cases of ototoxicity that occurred during the gentamicin clinical trials from 
1962-1969 and found the effect to be variable. Overall, there was no age 
difference between those with and without ototoxicity. However, patients with 
renal insufficiency and toxicity were younger. While not statistically 
significant, patients with normal kidneys and ototoxicity were older. 
Speculation about a possibly increased risk comes about for a variety of 
reasons. First of all, the aged have a higher incidence of adverse drug 
reactions (Hurwitz, 1969). This may be due to inadequate compliance with 
instructions, the presence of multiple diseases, and polypharmacy (Ljungberg 
& Nilsson-Ehle, 1987). Secondly, they seem to have a heightened sensitivity 
to certain drugs independent of serum concentration (Gordon & Preiksaitis, 
1988; Castledon et al., 1977). Finally, a host of changes take place in the 
aging body which may alter the pharmacokinetics of therapeutic agents 
(Ljungberg & Nilsson-Ehle, 1987 & Schmucker, 1984). 
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Of those which have an impact on aminoglycoside distribution, fluid 
shifts secondary to hemodynamic instability are frequently seen in critically ill 
surgical patients, many of whom are elderly (Dasta et al., 1988). Moreover, 
the elderly might theoretically have a smaller volume of distribution for water- 
soluble drugs, such as the aminoglycosides, due to a decrease in lean muscle 
mass and an increase in fat. For example, the percentage of body fat can 
increase from 18 to 36% in men and from 33 to 48% in women (Greenblatt et 
ah, 1982). This means that the same dose which produces appropriate levels 
in a 40-year-old may cause an overdose in a patient over the age of 70 with the 
same weight. Furthermore, the aging kidney suffers a 1-2% per year decline 
in blood flow, an eventual 50% reduction in glomerular filtration rate, a loss 
of functioning nephrons, a decrease in secretory/absorptive capacity, and a 
high incidence of spontaneous glomerular sclerosis (Schmucker, 1984). 
This decline in renal function can dramatically increase the half-life of 
substances, such as the aminoglycosides, which are renally eliminated, and it 
is of paramount importance (Vartia & Leikola, 1960). In fact, when controlled 
for renal function, hematocrit, fever, penicillin usage, and percentage of ideal 
body weight, Bauer & Blouin (1983) found that neither clearance, half-life, nor 
volume of distribution of gentamicin, tobramycin, or amikacin varied with age. 
Not only does this run counter to the notion that they would have a lower 
volume of distribution due to loss of lean body mass, but it also suggests that 
renal status and not age per se is the critical factor. 
In their review of the literature, Kjungberg & Nilsson-Ehle (1987) 
concluded that as a group, based on available data, the elderly had no 
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substantial reduction in metabolism or absorption of pharmacological agents. 
There is, however, substantial individual variation. The literature, 
unfortunately, is very sparse, and there may be other age-related factors which 
influence the pharmacokinetics of the aminoglycosides in ways which have yet 
to be elucidated. It is certainly difficult to perform adequately controlled 
studies due to the large number of variables such as multiple disease states, 
polypharmacy, and variations in activity levels which must be addressed. 
If the elderly do have an increased incidence, the question still remains 
as to why the aminoglycosides might preferentially affect the elderly. One 
possibility is that the 20-40% decrease in the number of vestibular hair cells 
associated with aging (Rosenhall, 1973) might simply leave elderly patients 
with fewer cells to lose before they become symptomatic. This is consistent 
with observations that patients treated with previous doses of aminoglycosides 
and patients with preexisting auditory impairment suffer from increased risk 
of vestibular toxicity (Gilman et al., 1985; and Wilson et al., 1984). Like the 
elderly, these patients might be expected to have fewer hair cells to lose before 
becoming symptomatic. Other researchers have speculated that chronic 
diseases and poor appetite may reduce some elderly patients to a state of 
semistarvation which they found to be one of the risk factors (Prazma et al., 
1983). Renal disease might also contribute. Creatinine clearance 
measurements are flawed because tubular secretion of creatinine causes 
overestimation of glomerular filtration rate (GFR), and this effect worsens in 
cases of declining GFR such as are seen in the aged (Kim et al., 1969). This 
may cause clinicians to overestimate renal function and administer more toxic 
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doses. Moreover, the replacement of lean body mass with adipose tissue seen 
in aging leads to a decrease in creatinine production which further complicates 
calculations (Greenblatt et al., 1982). Finally, as Fowler (1947) pointed out, 
elderly patients are less able to compensate for aminoglycoside-induced 
vestibular damage and might present themselves earlier. In that sense, the 
elderly, with their impaired ability to compensate for vestibular damage, are 
a unique population ideally suited for studying vestibular toxicity. 
FUTURE USAGE 
The question of whether the elderly are at increased risk is a significant 
one, and it is intimately related to the debate over the aminoglycosides’ place 
in current clinical practice. The three important considerations are side-effects, 
economics, and efficacy. The side effects have already been discussed, and 
their economic implications are magnified when examined in the setting of an 
elderly population. 
Those over the age of 65 currently make up 12% of the 251 million 
people in this country. By 2030 their ranks will swell to 21% of 317 million 
people (Waldo et al., 1989). Since they disproportionately consumed 36% of 
the $447 billion health care dollars spent last year, their physical health has a 
major impact on the economic health of the country both now and in the 
future. The monetary and human costs of an increase in dizziness among 
elderly patients therefore becomes significant. Dizziness and balance 
abnormalities are important risk factors in predicting the likelihood of falling 
(Tinetti et al., 1988; Tinetti et al., 1986). Roughly 30% of community-living 
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persons over the age of 65 are estimated to fall each year, and many of these 
falls are dizziness-related (Prudham & Evans, 1981). The decreased bone 
density seen with osteoporosis can transform a relatively minor fall into the 
tragedy of a hip fracture which carries a 15-30% one-year mortality rate in 
patients over the age of 60 (Kenzora, 1984). The economic cost is staggering, 
with the 1980 total annual cost of new hip fractures estimated at $2 billion 
(unpublished paper quoted in Baker & Harvey, 1985). 
There are other costs involved as well. Compared to some of the newer 
agents designed to replace them, the acquisition cost of aminoglycosides 
appears cheap at first glance. Since aminoglycosides are often used in 
combination with other agents, the added acquisition cost of using other agents 
must be added as well. Moreover, Eisenberg (1987) found that the cost of an 
individual patient with an episode of nephrotoxicity is $2,501 to the hospital 
and $5,376 to the third party payer. Therefore, the additional cost to the 
hospital per course of therapy, distributed among all patients using 
aminoglycosides, is $183 per patient. Furthermore, there is an additional cost 
of routinely monitoring drug serum levels, BUN, and serum creatinine that 
would not be incurred if safer antibiotics were used. This cost can range from 
$75-200 per patient (Sochalski et ah, 1988). Finally, when compared to single 
agent therapy, there is also the further expense incurred by increasing the 
workload of nurses, pharmacists, and other staff as well as the need for more 
equipment such as needles, bottles, etc. (Quintiliani et ah, 1986). 
The third consideration in deciding the place of aminoglycosides is 
therapeutic effectiveness. Efforts to modify aminoglycoside molecules to 
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reduce the toxicity without decreasing efficacy have failed and have largely 
been abandoned (Pancoast, 1988). Nevertheless, new classes of antibiotics and 
regimens of combination therapy have arisen and have shown some promise. 
For many CNS infections, third generation cephalosporins are now preferable 
when aerobic gram-negative organisms are involved (Pancoast, 1988). Beta- 
lactams are also replacing aminoglycosides for abdominal and pelvic mixed 
infections because of their superior gram-positive and anaerobic coverage 
(Pancoast, 1988; Quintiliani et al., 1986). For example, a study here at Yale 
has demonstrated that there is no major difference between cefotetan and 
combination therapy which includes aminoglycosides in the treatment of a 
variety of anaerobic infections (Sochalski et ah, 1988). 
In their review of the literature, DiPiro & Bowden (1989) concluded that 
aztreonam was at least as effective as aminoglycosides for lower respiratory, 
intra-abdominal, and other infections with gram-negative organisms including 
P. aeruginosa. Ceftazidime and cefoperazone have excellent activity against 
P. aeruginosa and are being used as single agent therapy in a variety of 
situations (Quintiliani et ah, 1986). Imipenem-cilistatin is another excellent 
alternative to the aminoglycosides (DiPiro & Bowden, 1989). 
In summary, the aminoglycoside antibiotics can reach high 
concentrations with a protracted half-life in the endolymph where they are 
toxic to vestibular hair cells. The exact mechanism is unknown, but elderly 
patients may have an increased risk. This study examined this special 
population and attempted to determine if, indeed, the elderly are at increased 
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risk of vestibular damage. When the aminoglycosides were first introduced, 
it was felt that although they had significant side-effects, their use was justified 
because of their impressive clinical effect in certain infections. With the 
introduction of new, safer antibiotics into our clinical armamentarium, it may 




A prospective observational cohort design was chosen for this study. 
This design is the least intrusive to both subjects and hospital staff while still 
allowing for effective collection of data. 
SUBJECTS AND SETTING 
The potential subjects in this study were all in-patients at the Yale-New 
Haven Hospital (New Haven, CT), the West Haven Veterans Administration 
Hospital (West Haven, CT), or St. Mary’s Hospital (Waterbury, CT) who were 
discharged between August and December of 1990. These facilities are, 
respectively, a university hospital, a veterans hospital, and a community 
hospital. Both male and female community-living and nursing home residents 
over the age of 65 were included. 
The study (exposed) group comprised those who were treated with an 
intravenous antibiotic course which included at least five days of any 
aminoglycoside. The control (unexposed) group had at least a five day course 
of antibiotics in which one of the control drugs was used. Since 
aminoglycosides are used predominantly for Pseudomonas coverage, beta- 
lactam antibiotics such as aztreonam, imipenem, ceftazidime, or one of the 
ant [-Pseudomonas penicillin (azlocillin, mezlocillin, carbenicillin, ticarcillin, or 
piperacillin) were selected as the control drugs due to their similar spectrum. 
Subjects who received more than one course of IV antibiotics during their 
hospitalization were included, but if they received aminoglycosides, they were 
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placed in the "exposed" group. Antibiotics administered topically, as eyedrops, 
or via bladder irrigation were ignored since their systemic effects would be 
minimal. 
An effort was made to include a broad a spectrum of subjects to make 
the results as generalizable as possible. Subjects were excluded, however, if 
they had preexisting severe renal disease (serum creatinine >3.5) or were 
hospitalized more than four months because it would have greatly complicated 
interpretation of results. Additionally, those subjects who were rehospitalized 
between the time of the index hospitalization and the time of the telephone 
interview were excluded. For practical purposes, subjects who were deaf, 
mute, or cognitively impaired (unable to provide accurate answers to survey 
questions), could not be contacted by telephone, or were in hospice at the time 
of the telephone interview were likewise excluded from the study. 
The names of potential subjects were obtained from lists provided by the 
hospital pharmacies or medical information services [Table 3]. The printouts 
from each hospital differed as to the screening criteria. The pharmacy printout 
from St.Mary’s listed 174 names of those who were at least 65 years old and 
who had at least one order for one of the study antibiotics. Examination of 
the pharmacy computer eliminated 114 persons due to an insufficient length 
of antibiotic use. The charts for the remaining 60 patients were then requested 
and examined. 
The Yale-New Haven Hospital printout provided 307 names of persons 
at least 65 years old along with a list of their antibiotic start and stop dates. 




SOURCE OF STUDY POPULATION 
HOSPITAL PHARMACY CHARTS CHARTS SUBJECTS 
LIST REQUESTED RECEIVED USED 
St. Mary’s 174 60 60 5 
YNHH 307 178 108 20 
WHVAH * 107 79 17 
Total 345 247 42 
Uncountable. 
Pharmacy list = list of potential subjects generated by pharmacy computer. 
Charts requested = subjects from printout who meet the criteria for age and 
antibiotic length as determined by the pharmacy computer. 
Charts received = the number of charts requested which were received from 
medical records. 
Subjects used = the number of subjects meeting the study criteria who were 
included in the data analysis. 
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requested. Unfortunately, the hospital policy does not allow incomplete charts 
to be used for research purposes. Seventy charts remained incomplete eight 
weeks after discharge and could therefore not be used in the study. 
The Veterans Hospital printout was essentially a list of orders placed to 
the pharmacy for stock items. The total number of subjects was uncountable 
since it listed all age groups, included multiple listings for each patient, was not 
alphabetized, and included requests for sterile saline, multivitamins, and other 
items which were not part of the study. Using the pharmacy computer, 
however, it was possible to pare the number of potential subjects who were 65 
or older and had received a sufficient course of antibiotics down to 79. 
Unfortunately, it was not possible to determine from the computer if all these 
subjects had been discharged or were still in the hospital. By the end of the 
pilot study 28 charts from the WHVAH were not available because the 
subjects were still in the hospital. 
There was only one refusal (an unexposed patient from YNHH) to 
participate in the study. Medical record data from this person were not 
included in the data analysis. Of those included in the study, five subjects 
came St. Mary’s, twenty came from YNHH, and seventeen came from the 
WHVAH. 
DATA 
Once the charts were received, all demographic data, past medical 
history, hospital course, medications, infecting organisms, surgical procedures, 
allergies, lab data, vital signs, length of hospitalization and antibiotic usage 
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were extracted from the medical record. Those subjects who met the inclusion 
criteria were contacted by telephone. 
Since the onset of vestibular toxicity can sometimes occur several weeks 
after discontinuation of the antibiotic (Neu & Bendush, 1976), the subjects 
were contacted by telephone two to eight weeks after their discharge to avoid 
missing any cases. This waiting period also allowed subjects to equilibrate in 
their home environment subsequent to their hospitalization. It was felt that 
increasing the time of contact beyond eight weeks after discharge could result 
in an increase in recall bias by the subjects. After informed consent was 
obtained, the subjects were asked if they had dizziness, what type they had, 
how severe it was, if they had a diagnosis for it, what medications they take 
for it, when it began, what brings it on, when was the most recent episode, and 
if they have had dizziness-related accidents. An effort was made to identify 
those cases in which dizziness could be attributed to known causes. Subjects 
were also asked about vision, hearing, and alcohol use. 
Although the author performed both the chart extraction and the 
telephone interview, these were done in batches to decrease the likelihood that 
knowledge of the antibiotic regimen would influence the interviewer. Hospital 
treatment was not discussed on the telephone. 
DEFINITION OF VARIABLES 
Renal insufficiency was estimated using BUN (nl=8-18 mg/dl) and 
creatinine (n]=0.5-1.2 mg/dl). Nutritional status was estimated using albumin 
(nl=3.5-5.0). Data on liver dysfunction were taken from the admission history 
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and physical and the discharge summary and based on the presence of cirrhosis 
or ascites. The most abnormal lab values from each subject throughout the 
admission were compiled to calculate a score on the standard APACHE II 
(Acute Physiology and Chronic Health Evaluation) Severity of Disease 
Classification System. Although Knaus et al. (1985) developed this scale as a 
predictor of hospital mortality in ICU patients, they suggested that it could 
also be used in research protocols to compare severity of disease between the 
exposed and unexposed groups. 
For the purpose of this study, dizziness was defined as a complaint of 
lightheadedness, disequilibrium, vertigo, or other ill-defined sensations of 
motion. "New-onset dizziness" was defined as dizziness that could not be 
ascribed to any other known process and which had begun since the 
hospitalization. "Increased severity" or "increased frequency" of dizziness since 
the hospitalization were based on the subjects’ subjective opinions. Those with 
new-onset dizziness were automatically considered to have both an increased 
severity and frequency of dizziness. A subject was considered to have 
"worsened dizziness" if he or she complained of either new-onset dizziness, an 
increase in the severity of dizziness, or an increase in the frequency of dizziness 
episodes. 
Assessment of post-hospitalization activity levels was based on a 
modified life-space diameter in which subjects were segregated according to 
their ability to get out of bed, leave the home, and leave the home without 
assistance (May et al, 1985). Those who left their home were asked to 
quantitate the number of blocks they felt they could walk on a given day. 
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Finally, obesity was estimated using self-reported height and weight to 
compute a body mass index (BMI), which is the weight in kilograms divided 
by the square of the height in meters (Stavig et al., 1984). 
STATISTICAL ANALYSIS 
Data were stored on an Optima 386SX personal computer, and 
statistical analyses were carried out using a standard statistical package (SAS 
Institute Inc. Cary, NC, 1987). Chi square analyses were used to analyze 
dichotomous data which had at least five items in each cell. The remainder of 
the dichotomous data were analyzed using the Fisher exact test. Student’s T- 




DATA SOURCES AND STATISTICS 







last systolic blood pressure 
last diastolic blood pressure 
maximum temperature 
APACHE II score 
length of hospitalization 
had surgery 
EtOH use #1 
EtOH use #2 
dizziness present 
new-onset dizziness 
increased frequency of dizziness 




leaves house alone 
blocks walked 
body mass index (BMI) 
hearing 
chart chi square 
chart Fisher exact 
chart chi square 
chart Student’s T-test 
chart Student's T-test 
chart Student’s T-test 
chart Student’s T-test 
chart Student’s T-test 
chart Student’s T-test 
chart Student’s T-test 
chart Student’s T-test 
chart chi square 
chart Fisher exact 
interview Fisher exact 
interview Fisher exact 
interview Fisher exact 
interview Fisher exact 
interview Fisher exact 
interview Fisher exact 
interview Fisher exact 
interview Fisher exact 
interview chi square 
interview Student's T-test 
interview Student’s T-test 
interview Fisher exact 
Worsened dizziness = report of new-onset dizziness or an increase in 




The average age (+/-SD) of the 42 subjects was 73.5 (+/- 6.23). Twenty 
four (57%) were male and 18 were female (43%). Thirty-five (83%) lwere 
white, three (7%) were black, and 4 (10%) did not have their race listed in the 
chart. 
There were 26 (62%) unexposed and 16 (38%) exposed subjects. 
Although the study was open to all persons with five or more days of 
treatment with any aminoglycoside, in actual fact the exposed group is only 
made up of subjects who received gentamicin. This probably reflects the local 
pattern of antibiotic prescription. Among the unexposed subjects, 15 received 
cefoperazone, 4 received ceftazidime, 3 received ticarcillin, and 4 received 
mezlocillin as their primary antibiotic [Table 5]. Again, all the control drugs 
were not represented. 
Of the 42 subjects, 10 (63%) of the exposed and 14 (54%) of the 
unexposed subjects were males, and there was no statistically significant 
difference in gender distribution between the populations by chi square (p = 
0.58). Fourteen (88%) exposed and 21 (81%) unexposed subjects were white. 
Two (12%) exposed and one (4%) unexposed subject were black. There was 
no statistically significant racial difference between the exposed and unexposed 
subjects by Fisher exact test (white: p = 0.69, black: p = 0.55). Four of the 
unexposed subjects did not have their race listed in the chart. The 
distribution of subjects having surgery during the admission in question was 




PRIMARY ANTIBIOTIC USED 
ANTIBIOTIC # OF SUBJECTS (%) 
gentamicin 16 (38%) 
cefoperazone 15 (36%) 
ceftazidime 4 (9.5%) 
mezlocillin 4 (9.5%) 
ticarcillin 3 (7.0%) 
The populations were compared using a student’s T test for age, 
maximum BUN, maximum creatinine, minimum albumin, last hematocrit, 
maximum temperature, last blood pressure, length of hospitalization, and body 
mass index. The Student’s T test was also used to compare self-reported 
activity levels (in blocks walked per day) and APACHE II scores. None of 
these variables were found to be statistically significant except length of 
hospitalization [Table 7]. Unexposed subjects remained in the hospital for 25 
(+/-17) days compared to exposed subjects who were hospitalized only 15 (+/- 
12) days (p = 0.036). 
When the exposed and unexposed subjects were compared by Fisher 












male 10 (63%) 14 (54%) 0.58 § 
female 6 (37%) 12 (46%) 
race 
white 14 (88%) 21 (81%) 0.69 If 
black 2 (12%) 1 (4%) 0.55 1 
unlisted 0 (0%) 4 (15%) 
surgery 
yes 9 (56%) 16 (62%) 0.74 § 
no 7 (44%) 10 (38%) 
bedridden 
yes 0 (0%) 1 (4%) i.oi 
no 16 (100%) 25 (96%) 
housebound 
yes 1 (6%) 4 (16%) 0.63 1 
no 15 (94%) 21 (80%) 
refused to answer 0 (0%) 1 (4%) 
can leave home alone 
yes 9 (56%) 16 (64%) 0.62 § 
no 7 (44%) 9 (32%) 
refused to answer 0 (0%) 1 (4%) 
alcohol use #1 
more than social 3 (38%) 3 (15%) 0.31 1 
none or social 13 (62%) 17 (62%) 
unlisted 8 (50%) 6 (23%) 
alcohol use #2 
more than social 5 (31%) 3 (12%) 0.23 
none or social 11 (69%) 22 (84%) 
refused 0 (0%) 1 (4%) 
hearing 
good 13 (81%) 23 (88%) 0.66 If 
poor 3 (19%) 3 (12%) 
diuretics 
used 6 (38%) 17 (68%) 0.044 § 
not used 10 (62%) 9 (32%) 
* = Alcohol use greater than "social" use or at least once per day. Variable #1 is 
obtained from the chart and #2 is obtained during the survey. 
** = Subject can hear a friend talking in room. 
= Fisher exact test 




COMPARISON OF EXPOSED AND UNEXPOSED SUBJECTS 
DIMENSIONAL DATA 
VARIABLE TEST EXPOSED UNEXPOSED P= 
Age range 




72.1 (6.1) 0.086 
BUN range 




29.8 (17.8) 0.79 
Creatinine range 




1.48 (0.54) 0.12 
Albumin range 




2.84 (0.92) 0.81 
Hematocrit range 




35.0 (5.2) 0.95 
Temperature range 




101.3 (1.4) 0.29 
Systolic BP range 




130.9 (18) 0.54 
Diastolic BP range 




















25.1 (6.5) 0.94 
APACHE II range 













Activity level is the reported number of blocks the subject can walk per day. 
p values calculated using a Student’s T-test. 
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the distributions of those who were bed-ridden or house-bound (p values 1.0 and 0.63 
respectively). When asked if they could leave their home without assistance, 9 (56%) 
exposed and 16 (64%) unexposed answered in the affirmative. There was no 
statistically significant difference between the populations by chi square test for this 
variable (p = 0.62). 
As a crude measure of visual acuity, subjects were asked if they could see well 
enough to recognize a friend across the room. All subjects answered in the 
affirmative. To assess hearing, subjects were asked if they could hear a friend talking 
to them from across the room. Thirteen (81%) exposed and 23 (88%) unexposed 
subjects felt they could do so. There was no significant difference between the 
populations by Fisher exact test (p = 0.66). When liver function was examined, it 
was noted that one unexposed subject had hepatitis of unknown etiology and one had 
cirrhosis (2/26, 7.7%). Only one (6.2%) exposed subject had liver pathology. In this 
case it was alcoholic hepatitis. The small number of subjects with liver disease makes 
it difficult to do statistical analysis, but the incidences appear similar. 
Although not statistically significant by Fisher exact test, alcohol use seemed 
to be higher in the exposed population than the unexposed population. This was true 
both for data obtained from the chart (p = 0.31) and data obtained over the (p = 
0.23). There was a 78% agreement between the chart information and the telephone 
survey for this variable. A kappa of 0.27 showed that there was poor agreement 
between the two reports of alcohol use. The difference between the populations for 
diuretic usage was statistically significant by chi square. Only 6 (38%) of exposed 




ASSESSMENT OF DIZZINESS 
Subjective reports of dizziness were assessed in the telephone interview. Five 
(31%) subjects reported experiencing episodes of feeling dizzy, lightheaded, or faint. 
Seven (27%) unexposed subjects in the exposed group reported these symptoms (p= 
1.0)[Table 8], For the question "Did you have this [dizziness] prior to your 
hospitalization?" 12.5% (2) of the exposed subjects as compared to 7.7% (2) of the 
unexposed subjects answered affirmatively (p = 0.63). When questioned as to an 
increase in the frequency of dizziness episodes since their hospitalization, two exposed 
(13%) and three (11.5%) unexposed subjects felt there was an increase (p = 1.0). A 
full 18.8% (3) of the exposed subjects reported an increase in the severity of dizziness 
compared to only 8.0% (2) of the unexposed subjects, but again this was not 
statistically significant by Fisher exact test (p = 0.36). Finally, when subjects 
reporting new-onset dizziness or an increase in severity or frequency of episodes were 
grouped together under the category of worsened dizziness, 18.8% of the exposed (3) 
and 11.5% (3) of the unexposed subjects had worsened dizziness since their 
hospitalization (Fisher exact p = 0.66). Based on these percentages, the relative risk 
of worsened dizziness for elderly patients after receiving at least five days of 
aminoglycoside therapy is 1.09 (95% confidence interval: 0.152-16.98). 
Of those who reported dizziness, two unexposed subjects and no exposed 
subjects suffered a fall between their discharge and the telephone call. One subject 
fell five times and reported dizziness prior to some of the falls. The other subject fell 
once and was not dizzy at the time. 
There were differences in the exposed and unexposed populations for four 
variables (age, length of hospitalization, diuretic use, and the number of blocks the 
subjects could walk) which were either statistically significant or close to it. Each 
variable was made binary. Age was divided into an older cohort (over 74 years old) 
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and a younger cohort (74 and under). Length of hospitalization was stratified into 
those hospitalized for 20 days or more and those hospitalized for less. The number 
of blocks walked was divided into two or less and three or more. Diuretic usage was 
already a binary variable. Table 9 presents the number of subjects and the 
percentages in each group. The sample size was not large enough to perform the 
Mantel-Haenszel chi square or relative risk. 
Diuretic usage was seen in 1 (17%) exposed and 2 (11%) unexposed subjects 
who reported worsened dizziness. Three (33%) of the exposed and only 1 (13%) 
unexposed subjects were 74 years old or older. A hospitalization of 20 or more days 
was seen in 2 (67%) of the exposed and 2 (15%) of the unexposed subjects who 
reported worsened dizziness. Finally, worsened dizziness was reported in 2 (25%) 




COMPARISON OF EXPOSED AND UNEXPOSED SUBJECTS 
DIZZINESS OUTCOME 
VARIABLE EXPOSED 
n = 16 
UNEXPOSED 
n = 26 
P= 
dizziness (new or old) 
present 5 (31%) 7 (27%) 1.0 
absent 11 (69%) 19 (73%) 
new-onset dizziness 
present 2 (13%) 2 (8%) 0.63 
absent 14 (87%) 24 (92%) 
dizziness frequency 
increased 2 (13%) 3 (12%) 1.0 
decreased or unchanged 13 (81%) 23 (88%) 
refused to answer 1 (6%) 0 (0%) 
dizziness severity 
increased 3 (19%) 2 (8%) 0.36 
decreased or unchanged 13 (81%) 23 (88%) 
refused to answer 0 (0%) 1 (4%) 
worsened dizziness 
present 3 (19%) 3 (12%) 0.66 
absent 13 (81%) 23 (88%) 
p values calculated using Fisher exact test. 
New-onset dizziness - reports of dizziness which was not present prior to 
hospitalization. 
Worsened dizziness = reports of either new-onset dizziness or an increase in frequency 




STRATIFICATION OF WORSENED DIZZINESS* 
BY POTENTIAL CONFOUNDING VARIABLES 
VARIABLE SUBJECTS REPORTING WORSENED DIZZINESS 
EXPOSED (%) UNEXPOSED (%) 








Age over 73 years old 







20 or more days (n = 17) 






3 or more (n=12) 





Worsened dizziness^ reports of either new-onset dizziness or an increase in the 




Elderly subjects who received in-hospital aminoglycosides and elderly 
subjects who did not receive these agents were compared for subjective 
reporting of dizziness. This pilot study demonstrated a trend in which the 
aminoglycoside-exposed population subjectively reported a higher rate of new- 
onset dizziness, worsened dizziness, or increased severity of dizziness than those 
who had not received them. This trend shows a 5-11% higher incidence of 
symptoms in those who received aminoglycosides, and it is larger than the 2- 
2.5% range of historical controls for gentamicin toxicity (Jackson & Arcieri, 
1971; Arcieri et al., 1970). This suggests that elderly patients may have an 
increased risk of aminoglycoside-induced dizziness. 
It is possible that this population differs from the populations studied 
in the other protocols in some significant way other than age. Moreover, the 
trend was not statistically significant, so the small sample size did not permit 
a more definitive conclusion. If the elderly do not actually have an increased 
risk of dizziness, there are many reasons why a trend could have artifactually 
been found. First, the choice of antibiotic, and hence the separation into 
exposed and unexposed groups, was not randomized or even controlled by the 
investigators. This could lead to a susceptibility bias (Horwitz et al., 1985) 
since the reasons for administering (or not administering) aminoglycosides 
could somehow be related to a predisposition to vestibular toxicity. For 
example, since clinicians who felt that subjects had a high risk for 
aminoglycoside-induced side-effects would be less likely to use these agents, 
one would expect to find less dizziness in the exposed group. 
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Secondly, the observed trend could also result from unmeasured 
differences between the exposed and unexposed populations. No statistically 
significant differences, however, were found between the populations for 
variables such as age, gender, race, various lab values, occurrence of surgery 
during the admission, hearing, vision, or level of activity. Commonly cited risk 
factors for aminoglycoside vestibular toxicity such as renal insufficiency, 
obesity, liver dysfunction, starvation, and peak temperature were surveyed, and 
no statistically significant difference between the populations were noted. 
Severity of illness was assessed using APACHE II scores, and although 
unexposed subjects were hospitalized longer, there was no statistically 
significant difference between the two populations. Maximum BUN and 
creatinine were used as a crude measure of hydration status. The hospital 
charts did not contain sufficient information to examine preexisting auditory 
impairment or the effects of noise on these patients. Moreover, since all 
patients did not have blood culture results, it was not possible to accurately 
assess bacteremia. Finally, since serum levels of the beta-lactams are not 
routinely measured, it was not possible to compare the populations for possible 
overdosage of antibiotics. 
Nevertheless, there were some significant differences between the two 
study populations. When the dizziness outcomes were stratified by these 
variables, exposed subjects still had a higher percentage of reports of worsened 
dizziness than unexposed subjects in both diuretic groups, the older age group, 
the longer hospitalization group, and the less active group. Exposed and 
unexposed subjects were equal in their reporting of worsened dizziness in the 
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most active group and the short hospitalization group, but a higher percentage 
of the exposed population came from these two groups. By having a higher 
percentage of the exposed subjects in subpopulations where there was no 
difference between exposed and unexposed subjects in terms of worsened 
dizziness, the overall magnitude of the difference between the exposed and 
unexposed subjects would therefore be lower. There were more reports of 
dizziness among unexposed subjects in the younger age group than among the 
exposed subjects. Since 69% of the unexposed subjects were younger while 
only 44% of the exposed subjects were younger, this would increase the 
incidence of dizziness seen in the unexposed group. Thus the net effect of the 
latter three confounding variables seems to be to decrease the observed trend. 
Although proper statistics were not done because of the sample size, taken 
together the results indicate that older subjects who were less active and had 
longer hospitalizations had a higher incidence of dizziness when given 
aminoglycoside antibiotics. 
The sample size was the greatest limitation of the study. Given the 
breadth of the information collected in this study, it would have been very 
interesting to use a variety of other statistical tests, such as multivariant 
analysis, on the data. This was not possible due to the small sample size. 
Additional subjects would also be needed to compare the populations for 
occurrence of specific types of concurrent medical problems, surgical 
procedures, and medications. Another limitation of the study was that only 
a small percentage of the potential population was utilized. Although efforts 
were made to include a broad a spectrum of subjects, a large number of 
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subjects were unavoidably excluded due to restrictions on the review of medical 
charts. 
Based on the current sample size, the power of this study to demonstrate 
at the 5% level a difference the magnitude of the observed trend is very small. 
Assuming the frequencies noted in this study are the actual frequencies which 
would be seen if the entire population over the age of 65 was sampled, the 
sample size needed to increase the power to 85% at an alpha of 5% would be 
roughly 250 subjects in each arm for a total of 500 subjects. Using the 
maximum rate of data collection, it would require approximately three years 
to complete the study. 
If this pilot study had detected an actual difference secondary to 
aminoglycoside use, it could be due to the myriad of pharmacokinetic changes 
inherent in aging. Bauer & Blouin’s (1983) work, though, suggests that these 
changes do not apply to aminoglycosides. More likely, aminoglycoside usage 
takes its toll on the vestibular hair cell population in all patients regardless of 
age even if given subtherapeutically in a manner similar to the effect on rat 
kidneys seen by Houghton et al. (1988). Therefore, the age-associated decline 
in the number of vestibular hair cells observed by Rosenhall (1973) and an 
inability to adequately compensate for their loss simply leaves elderly patients 
with fewer hair cells to lose before they become symptomatic. 
Clearly, more work needs to be done in this area. Since many of the 
other studies used the relatively insensitive thermal test as a determination of 
whether toxicity existed, it is possible that they missed the more subtle 
differences, such as the increase in severity of dizziness, which were seen with 
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the telephone survey. The advantage of the thermal test is that it provides 
more objective data than the telephone survey. Future studies might benefit 
from integrating both approaches into the protocol. Although only gentamicin 
was actually used, this study also attempted to examine all the aminoglycosides 
as a group. By specifically focusing on gentamicin, which has a higher rate of 
vestibular toxicity, future studies would require fewer subjects to demonstrate 
a difference between the study groups. 
Despite the length of time required, the trend indicates it is useful to 
pursue this line of research. An increase in dizziness symptoms in a geriatric 
population would be clinically significant. Dizziness can lead to falls and to 
the tragedy of a hip fracture. Although only two subjects fell during the brief 
tenure of this study, one would expect that the number of falls would increase 
as the subjects recuperated from their hospitalizations and became more active. 
Those with dizziness or balance abnormalities might also be expected to fall 
more frequently. Continuation of the study might settle the debate over the 
possibility of increased risk among geriatric patients, and through more careful 
antibiotic use, might decrease the incidence of life-threatening hip fractures and 
other injuries. 
SUMMARY 
The significant toxicities of the aminoglycosides are well-recognized, and 
vestibular toxicity is already known to be one of them. This study focused on 
the question of whether the elderly are at an increased risk of aminoglycoside- 
induced vestibular damage. Subjects who were exposed to aminoglycosides 
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and those who were unexposed were compared for subjective reporting of 
dizziness. Those subjects exposed to aminoglycosides reported a higher 
incidence of dizziness symptoms than both the unexposed subjects and the 
historical controls. Although the results were not statistically significant, it 
suggests that the elderly may have an increased risk of dizziness with 
aminoglycoside use. 
The failure of this study to conclusively demonstrate a higher incidence 
may in part be due to the study's low power. Continuation of this study, 
therefore, may offer a more complete understanding of this economically 
important problem. Given the aminoglycosides’ incredible clinical success, it 
may not yet be possible to substitute them for other antibiotics. Nevertheless, 
their known toxicities should imbue clinicians with a healthy sense of caution 
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